A Phase 1 interventional study of Palivizumab and Placebo in Healthy Adult Participants, sponsored by mAbxience Research S.L.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-04.
Sponsored by mAbxience Research S.L. (part of Fresenius Kabi) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Double-Blind, Randomised, Placebo-Controlled Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated with Respiratory Syncytial Virus (RSV).
As no data exists for Palivizumab in the RSV human challenge model, this exploratory study is therefore planned to establish the margins of effect and variance of prophylactically administered Palivizumab within the RSV-A Memphis 37b challenge model in healthy adult volunteers.
The study will be performed in adults aged 18-55 years, in two parts.
If there are no safety concerns in Part 1, and PK analysis of Palivizumab treated participants confirm the modelling of 8mg/Kg to be appropriate, Part 2 will commence with the planned 8mg/Kg treatment dose. However, if PK analysis of Part 1 suggests that 8mg/kg may be insufficient dose to provide suitable efficacious coverage in Part 2, then Part 2 will proceed with a dose of 15mg/Kg.
mAbxience Research S.L. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
First submitted before mAbxience Research S.L. became part of Fresenius Kabi.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following criteria are applicable to female participants participating in the study.
<!-- -->
The following criteria apply to female and male participants:
<!-- -->
f. True abstinence - sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.
b) Male participants must agree to the contraceptive requirements below at entry to quarantine and continuing until 90 days after the date of Viral challenge / last dosing with the medicinal product (IMP) (whichever occurs last):
c) In addition to the contraceptive requirements above, male participants must agree not to donate sperm following discharge from quarantine until 90 days after the date of Viral Challenge/last dosing with IMP (whichever occurs last).
Exclusion Criteria:
Medical History
a) Any history or evidence of any other or currently active systemic comorbidities including psychiatric disorders (includes participants with a history of depression and/or anxiety).
b) And/or other major disease that, in the opinion of the Investigator, may put the participant at undue risk, or interfere with a participant completing the study and necessary investigations.
The following conditions apply:
Any concurrent serious illness including history of that may interfere with the aims of the study or a participant completing the study. Basal cell carcinoma within 5 years of initial diagnosis or with evidence of recurrence is also an exclusion.
o Participants with a history of psychiatric illness including depression and/or anxiety of any severity within the last 2 years can be included if the Patient Health Questionnaire (PHQ-9) and / or the Generalised Anxiety Disorder Questionnaire (GAD-7) is less than or equal to 4. Participants with a PHQ-9 or GAD-7 score of between 5 and 9 may be included following consultation with a Senior Physician (Clinical Lead for Screening) who may advise further consultation with the PI.
o Participants reporting physician diagnosed migraine can be included provided there are no associated neurological symptoms such as hemiplegia or visual loss. Cluster headache/migraine or prophylactic treatment for migraine is an exclusion.
Females who:
a) For Part 2 of the study: Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the aims of the study and in particular any of the nasal assessments or viral challenge, (historical nasal polyps can be included, but large nasal polyps causing current and significant symptoms and/or requiring regular treatments in the last month will be excluded).
b) Any clinically significant history of epistaxis (large nosebleeds) within the last 3 months of the first study visit and/or history of being hospitalized due to epistaxis on any previous occasion.
c) Any nasal or sinus surgery within 3 months of the first study visit. Prior or Concomitant Medications and Assessments
For Part 2 of the study:
a) Receipt of any drug within 3 months prior to the planned date of viral challenge/first dosing with IMP (whichever occurs first).
b) Receipt of three or more investigational drugs within the previous 12 months prior to the planned date of viral challenge/first dosing with IMP (whichever occurs first).
For Part 2 of the study:
c) Prior inoculation with a virus from the same virus-family as the challenge virus.
d) Prior participation in another human viral challenge study with a respiratory virus in the preceding 3 months, taken from the date of viral challenge in the previous study to the date of expected viral challenge in this study
a) Confirmed positive test for drugs of abuse on first study visit. One repeat test allowed at PI discretion.
b) History or presence of alcohol addiction, or excessive use of alcohol (weekly intake in excess of 28 units alcohol; 1 unit being a half glass of beer, a small glass of wine or a measure of spirits), or excessive consumption of xanthine containing substances (e.g. daily intake in excess of 5 cups of caffeinated drinks e.g. coffee, tea, cola).
For Part 2 of the study:
A (FEV1) \< 80%.
Positive (HIV), active hepatitis A (HAV), B (), or C () test.
Other
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sodium Chloride 0.9% Solution (Normal Saline)
Drug: Placebo · Other: RSV-A Memphis 37b virus
Sterile vial 50mg/0.5mL
Drug: Palivizumab · Other: RSV-A Memphis 37b virus
Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min
Also known as: Synagis™
Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min
Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)
Mean Serum Concentrations (Cmax) for Open-label Palivizumab (Part 1) on Day 12.
The PK assessment up to and including Day 12 exposure was used as a decision information for the dose to be given to participants in Part 2. Pharmacokinetic exposure data from at least 5 out of 6 participants were required for dose decision making with a projected exposure of ≥40 μg/mL on Day 12 according to the protocol. This was achieved after administration of a single IV dose of Palivizumab at 8 mg/kg. Therefore, a dose of 8 mg/kg was chosen for Part 2.
Time frame: In Part 1: before the start of infusion; at end of infusion,15 minutes and 0.5, 1, 4, 8, and 12 hours after infusion; and at 1, 2, 3, 7, and 12 days after infusion.
Area Under the Viral Load-time Curve (VL-AUC) as Determined by Polymerase Chain Reaction (qRT-PCR) on Nasal Samples, for Double-blind Palivizumab or Placebo (Part 2).
RSV viral load of RSV-A Memphis 37b as determined by qRT-PCR on nasal samples collected twice daily: Assessment of the Area under the viral load-time curve (VL-AUC)
Time frame: From two days post viral challenge (Day 2) to the end of quarantine (Day 12) in Part 2 on nasal samples collected twice daily.
qRT-PCR Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2).
Peak viral load of RSV-A Memphis 37b as determined by qRT-PCR on nasal samples collected twice daily.
Time frame: From two days post viral challenge (Day 2) to the end of quarantine (Day 12) in Part 2
Area Under the Viral Load-time Curve (VL-AUC) as Determined by Cell Culture on Nasal Samples, for Double-blind Palivizumab (Part 2).
RSV Viral Load of RSV-A Memphis 37b as Determined by Cell Culture on Nasal Samples collected twice daily: Area under the viral load-time curve (VL-AUC) of RSV-A Memphis 37b
Time frame: From two days post viral challenge (Day 2) to the end of quarantine (Day 12) in Part 2 on nasal samples collected twice daily.
Cell Culture Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2).
Peak Viral Load of RSV-A Memphis 37b as Determined by Cell Culture on Nasal Sample
Time frame: From Day 2 to Day 12 in Part 2
Number of Participants With Laboratory-confirmed Infection of RSV-A Memphis 37b in Nasal Samples (Variant 1) for Double-blind Palivizumab or Placebo (Part 2).
Percentage of Participants Infected Post-viral Challenge (Infectivity Status and Rate): occurrence of at least 2 positive "quantifiable" qRT-PCR measurements in nasal samples. Laboratory-confirmed infection (variant 1): At least 2 positive quantifiable detections by viral load qRT-PCR assay specific for the challenge virus, reported within 4 consecutive scheduled assessments and from 2 independent samples from Day 2 until discharge and/or 1 positive detection by viral load qRT-PCR assay, specific for the challenge virus, in which an aliquot of the same sample has also tested positive in a viral culture assay appropriate for detecting the challenge virus from Day 2 until discharge.
Time frame: From Day 2 to Day 12 in Part 2
Number of Participants With Laboratory-confirmed Infection of RSV-A Memphis 37b in Nasal Samples (Variant 2), for Double-blind Palivizumab or Placebo (Part 2).
Percentage of Participants Infected Post-viral Challenge (Infectivity Status and Rate): Occurrence of at least 2 positive "detectable" qRT-PCR measurements in nasal samples. Laboratory-confirmed infection (variant 2): At least 2 positive detectable assessments by viral load qRT-PCR assay specific for the challenge virus, reported within 4 consecutive scheduled assessments and from 2 independent samples from Day 2 until discharge and/or 1 positive detection by viral load qRT-PCR assay, specific for the challenge virus, in which an aliquot of the same sample has also tested positive in a viral culture assay appropriate for detecting the challenge virus from Day 2 until discharge.
Time frame: From Day 2 to Day 12 in Part 2
Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Duration, for Double-blind Palivizumab or Placebo (Part 2).
Estimation of the duration of viral shedding by the number of days with quantifiable qRT-PCR measurements in nasal samples starting 2 days post viral challenge (Day 2) up to the end of quarantine.
Time frame: From Day 2 to Day 12 in Part 2
Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Time to Peak Viral Load, for Double-blind Palivizumab or Placebo (Part 2).
Estimation of the duration of viral shedding by the time to peak viral load of RSV by quantifiable qRT-PCR.
Time frame: From Day 2 to Day 12 in Part 2
Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Peak Viral Load, for Double-blind Palivizumab or Placebo (Part 2).
Peak viral load of RSV-A Memphis 37b as defined by the maximum viral load determined by quantifiable qRT PCR measurements in nasal samples starting 2 days post viral challenge (Day 2) up to the end of quarantine.
Time frame: From Day 2 to Day 12 in Part 2
Total Symptom Score (TSS)-Time Curve (AUC) Collected Daily in the Participant Symptom Diary Card
Mean TSS values (collected daily in the symptom diary card) over time. Symptoms were collected using the hVIVO (services provider) symptom diary card. Several symptoms (such as runny nose, sore throat, earache, etc) in the 13-item questionnaire were graded on a scale of 0-3 (grade 0: No symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with me doing my normal daily activities; grade 3: Quite bothersome most or all of the time, and it stops me participating in activities). Shortness of breath and wheeze have an additional grade 4: Symptoms at rest. The total symptom score (TSS) was determined as the sum of the symptom scores ranging from 0.0 (min) to 41(max) \[or a maximum of 41x11.33=464.67 depending on what the reviewer is asking\] using a 13-items self-reported diary card. 11.33 is the number of days symptom diary cards were included (Day +1 morning dairy card to Day 12 morning diary card). Higher scores mean worse outcome.
Time frame: From two days post viral challenge (Day 2) to the end of quarantine (Day 12) in Part 2 on nasal samples collected twice daily.
Peak Symptom Scores
Peak symptom scores for symptoms collected daily in the participant symptom diary card. Symptoms (such as runny nose, sore throat, earache, etc) were collected using the 13-item hVIVO symptom questionnaire and were graded on a scale of 0-3 (grade 0: No symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with me doing my normal daily activities; grade 3: Quite bothersome most or all of the time, and it stops me participating in activities). Shortness of breath and wheeze have an additional grade 4: Symptoms at rest. The total symptom score (TSS) was determined as the sum of the symptom scores ranging from 0.0 (min) to 41(max) \[or a maximum of 41x11.33=464.67 depending on what the reviewer is asking\] using a 13-items self-reported diary card. 11.33 is the number of days symptom diary cards were included (Day +1 morning dairy card to Day 12 morning diary card). Higher scores mean worse outcome.
Time frame: From Day 2 to Day 12 in Part 2
Total Weight of Nasal Discharge Produced
Nasal Discharge Collection from Paper Tissues by means of the total weight of nasal discharge produced.
Time frame: From Day 1 to Day 12 in Part 2
Total Number of Tissues Used by Participants
Nasal Discharge Collection from Paper Tissues by means of the total number of tissues used.
Time frame: From Day 1 to Day 12 in Part 2
Number of Participants With Laboratory-confirmed Virus-like Illness (Variant 1) Using Viral Shedding Variant 1, for Double-blind Palivizumab or Placebo (Part 2).
Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.
Time frame: From Day 2 to Day 12 in Part 2
The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 1) Using Viral Shedding Variant 2, for Double-blind Palivizumab or Placebo (Part 2).
Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.
Time frame: From Day 2 to Day 12 in Part 2
The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 2) Using Viral Shedding Variant 1, for Double-blind Palivizumab or Placebo (Part 2).
Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.
Time frame: From Day 2 to Day 12 in Part 2
The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 2) Using Viral Shedding Variant 2, for Double-blind Palivizumab or Placebo (Part 2).
Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.
Time frame: From Day 2 to Day 12 in Part 2
Cmax
Evaluation of Palivizumab PK levels throughout the study, by means of Cmax after intravenous administration of Palivizumab.
Time frame: Before the start of infusion; at end of infusion, 15 minutes and 0.5, 1, 4, 8, and 12 hours after infusion; and at 1, 2, 3, 7 and 12 days after infusion (Part 1) or at 1, 2, 3, 7, 13, 21, and 29 days after infusion (Part 2)
Tmax
Palivizumab PK levels throughout the study, by means of Tmax after intravenous administration of Palivizumab.
Time frame: Before the start of infusion; at end of infusion, 15 minutes and 0.5, 1, 4, 8, and 12 hours after infusion; and at 1, 2, 3, 7, and 12 days after infusion (Part 1) or at 1, 2, 3, 7, 13, 21, and 29 days after infusion (Part 2)
Safety Adults: Number of Participants With Adverse Events (AEs)
Incidence of AEs, treatment-emergent AEs (TEAEs), serious AEs (SAEs) and; drug-related or challenge-virus related TEAEs and SAEs
Time frame: From Day 1 to Day 18 in Part 1 and from Day 1 to Day 28 in Part 2
Immunogenicity: Number of Participants Positive for Anti-palivizumab Antibody (ADA)
Determination of the incidence of anti-palivizumab ADA (number and percent of participants tested positive for anti-palivizumab ADA). ADA positive participant: baseline negative and any sample after treatment positive, or baseline positive and titre increased 4- to 9-fold after treatment) before the dose of palivizumab and at scheduled post-dose assessments.
Time frame: Part 2: prior to infusion with Palivizumab and 7, 13, and 29 days post Palivizumab infusion.
| Milestone | Open-label Palivizumab (Part 1) | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|---|
| Started | 6 | 0 | 0 |
| Completed | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Open-label Palivizumab (Part 1) | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|---|
| Started | 0 | 25 | 25 |
| Completed | 0 | 25 | 25 |
| Not completed | 0 | 0 | 0 |
The PK assessment up to and including Day 12 exposure was used as a decision information for the dose to be given to participants in Part 2. Pharmacokinetic exposure data from at least 5 out of 6 participants were required for dose decision making with a projected exposure of ≥40 μg/mL on Day 12 according to the protocol. This was achieved after administration of a single IV dose of Palivizumab at 8 mg/kg. Therefore, a dose of 8 mg/kg was chosen for Part 2.
| μg/mL | Open-label Palivizumab (Part 1) | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|---|
| Mean Serum Concentrations (Cmax) for Open-label Palivizumab (Part 1) on Day 12. | 71.2 ± 6.11 | — | — |
RSV viral load of RSV-A Memphis 37b as determined by qRT-PCR on nasal samples collected twice daily: Assessment of the Area under the viral load-time curve (VL-AUC)
| Log10 copies*day/mL | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Area Under the Viral Load-time Curve (VL-AUC) as Determined by Polymerase Chain Reaction (qRT-PCR) on Nasal Samples, for Double-blind Palivizumab or Placebo (Part 2). | 11.68 ± 15.36 | 9.94 ± 12.38 |
Peak viral load of RSV-A Memphis 37b as determined by qRT-PCR on nasal samples collected twice daily.
| Log10 copies/mL | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| qRT-PCR Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2). | 3.66 ± 2.42 | 3.11 ± 2.65 |
RSV Viral Load of RSV-A Memphis 37b as Determined by Cell Culture on Nasal Samples collected twice daily: Area under the viral load-time curve (VL-AUC) of RSV-A Memphis 37b
| Log10 PFU*day/mL | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Area Under the Viral Load-time Curve (VL-AUC) as Determined by Cell Culture on Nasal Samples, for Double-blind Palivizumab (Part 2). | 2.05 ± 5.29 | 1.64 ± 3.43 |
Peak Viral Load of RSV-A Memphis 37b as Determined by Cell Culture on Nasal Sample
| Log10 PFU/mL | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Cell Culture Peak Viral Load for Double-blind Palivizumab or Placebo (Part 2). | 0.60 ± 1.47 | 0.88 ± 1.41 |
Percentage of Participants Infected Post-viral Challenge (Infectivity Status and Rate): occurrence of at least 2 positive "quantifiable" qRT-PCR measurements in nasal samples. Laboratory-confirmed infection (variant 1): At least 2 positive quantifiable detections by viral load qRT-PCR assay specific for the challenge virus, reported within 4 consecutive scheduled assessments and from 2 independent samples from Day 2 until discharge and/or 1 positive detection by viral load qRT-PCR assay, specific for the challenge virus, in which an aliquot of the same sample has also tested positive in a viral culture assay appropriate for detecting the challenge virus from Day 2 until discharge.
| Participants | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Number of Participants With Laboratory-confirmed Infection of RSV-A Memphis 37b in Nasal Samples (Variant 1) for Double-blind Palivizumab or Placebo (Part 2). | 13 | 12 |
Percentage of Participants Infected Post-viral Challenge (Infectivity Status and Rate): Occurrence of at least 2 positive "detectable" qRT-PCR measurements in nasal samples. Laboratory-confirmed infection (variant 2): At least 2 positive detectable assessments by viral load qRT-PCR assay specific for the challenge virus, reported within 4 consecutive scheduled assessments and from 2 independent samples from Day 2 until discharge and/or 1 positive detection by viral load qRT-PCR assay, specific for the challenge virus, in which an aliquot of the same sample has also tested positive in a viral culture assay appropriate for detecting the challenge virus from Day 2 until discharge.
| Participants | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Number of Participants With Laboratory-confirmed Infection of RSV-A Memphis 37b in Nasal Samples (Variant 2), for Double-blind Palivizumab or Placebo (Part 2). | 15 | 15 |
Estimation of the duration of viral shedding by the number of days with quantifiable qRT-PCR measurements in nasal samples starting 2 days post viral challenge (Day 2) up to the end of quarantine.
| days | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Duration, for Double-blind Palivizumab or Placebo (Part 2). | 2.84 ± 3.01 | 2.61 ± 2.98 |
Estimation of the duration of viral shedding by the time to peak viral load of RSV by quantifiable qRT-PCR.
| days | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Time to Peak Viral Load, for Double-blind Palivizumab or Placebo (Part 2). | 7.21 ± 2.98 | 7.03 ± 2.35 |
Peak viral load of RSV-A Memphis 37b as defined by the maximum viral load determined by quantifiable qRT PCR measurements in nasal samples starting 2 days post viral challenge (Day 2) up to the end of quarantine.
| Log10 copies/mL | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Viral Shedding of RSV-A Memphis 37b in Nasal Samples in Terms of Peak Viral Load, for Double-blind Palivizumab or Placebo (Part 2). | 3.66 ± 2.42 | 3.11 ± 2.65 |
Mean TSS values (collected daily in the symptom diary card) over time. Symptoms were collected using the hVIVO (services provider) symptom diary card. Several symptoms (such as runny nose, sore throat, earache, etc) in the 13-item questionnaire were graded on a scale of 0-3 (grade 0: No symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with me doing my normal daily activities; grade 3: Quite bothersome most or all of the time, and it stops me participating in activities). Shortness of breath and wheeze have an additional grade 4: Symptoms at rest. The total symptom score (TSS) was determined as the sum of the symptom scores ranging from 0.0 (min) to 41(max) \[or a maximum of 41x11.33=464.67 depending on what the reviewer is asking\] using a 13-items self-reported diary card. 11.33 is the number of days symptom diary cards were included (Day +1 morning dairy card to Day 12 morning diary card). Higher scores mean worse outcome.
| Total Symptom Score scale-points*day | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Total Symptom Score (TSS)-Time Curve (AUC) Collected Daily in the Participant Symptom Diary Card | 13.84 ± 14.72 | 7.27 ± 9.03 |
Peak symptom scores for symptoms collected daily in the participant symptom diary card. Symptoms (such as runny nose, sore throat, earache, etc) were collected using the 13-item hVIVO symptom questionnaire and were graded on a scale of 0-3 (grade 0: No symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with me doing my normal daily activities; grade 3: Quite bothersome most or all of the time, and it stops me participating in activities). Shortness of breath and wheeze have an additional grade 4: Symptoms at rest. The total symptom score (TSS) was determined as the sum of the symptom scores ranging from 0.0 (min) to 41(max) \[or a maximum of 41x11.33=464.67 depending on what the reviewer is asking\] using a 13-items self-reported diary card. 11.33 is the number of days symptom diary cards were included (Day +1 morning dairy card to Day 12 morning diary card). Higher scores mean worse outcome.
| score on a scale | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Peak Symptom Scores | 4.16 ± 3.45 | 2.54 ± 3.32 |
Nasal Discharge Collection from Paper Tissues by means of the total weight of nasal discharge produced.
| g | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Total Weight of Nasal Discharge Produced | 22.23 ± 41.52 | 7.66 ± 14.92 |
Nasal Discharge Collection from Paper Tissues by means of the total number of tissues used.
| tissues | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Total Number of Tissues Used by Participants | 32.04 ± 42.74 | 20.38 ± 21.88 |
Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.
| Participants | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Number of Participants With Laboratory-confirmed Virus-like Illness (Variant 1) Using Viral Shedding Variant 1, for Double-blind Palivizumab or Placebo (Part 2). | 11 | 5 |
Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.
| Participants | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 1) Using Viral Shedding Variant 2, for Double-blind Palivizumab or Placebo (Part 2). | 11 | 5 |
Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.
| Participants | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 2) Using Viral Shedding Variant 1, for Double-blind Palivizumab or Placebo (Part 2). | 13 | 11 |
Illness Post-viral challenge measured by means of the proportion of participants with any symptom ≥grade 1 for the evaluable population.
| Participants | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| The Occurrence of Laboratory-confirmed Virus-like Illness (Variant 2) Using Viral Shedding Variant 2, for Double-blind Palivizumab or Placebo (Part 2). | 15 | 14 |
Evaluation of Palivizumab PK levels throughout the study, by means of Cmax after intravenous administration of Palivizumab.
| μg/mL | Open-label Palivizumab (Part 1) | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|---|
| Cmax | 262 ± 35.6 | — | 283 ± 46.5 |
Palivizumab PK levels throughout the study, by means of Tmax after intravenous administration of Palivizumab.
| hours | Open-label Palivizumab (Part 1) | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|---|
| Tmax | 0.90 (0.57 to 1.70) | — | 0.92 (0.53 to 1.77) |
Incidence of AEs, treatment-emergent AEs (TEAEs), serious AEs (SAEs) and; drug-related or challenge-virus related TEAEs and SAEs
| participants | Open-label Palivizumab (Part 1) | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|---|
| Any AE | 0 | 12 | 14 |
| Any TEAE | 0 | 12 | 14 |
| Any TEAE related to the study drug | 0 | 1 | 4 |
| Any TEAE related to the challenge virus | 0 | 5 | 8 |
| Any SAE | 0 | 0 | 1 |
| Any SAE leading to study discontinuation | 0 | 0 | 0 |
| Any SAE related to the study treatment | 0 | 0 | 0 |
| Any SAE related to the challenge virus | 0 | 0 | 1 |
| Any death | 0 | 0 | 0 |
Determination of the incidence of anti-palivizumab ADA (number and percent of participants tested positive for anti-palivizumab ADA). ADA positive participant: baseline negative and any sample after treatment positive, or baseline positive and titre increased 4- to 9-fold after treatment) before the dose of palivizumab and at scheduled post-dose assessments.
| Participants | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|
| Immunogenicity: Number of Participants Positive for Anti-palivizumab Antibody (ADA) | 0 |
Collected over Day 1 to Day 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Placebo (Part 2) | 0/25 (0%) | 0/25 (0%) | 12/25 (48%) |
| Double-blind Palivizumab (Synagis™) (Part 2) | 0/25 (0%) | 1/25 (4%) | 14/25 (56%) |
| Event | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| MyocarditisCardiac disorders | 0/25 | 1/25 |
| Event | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
|---|---|---|
| Alanine Aminotransferase IncreasedInvestigations | 6/25 | 9/25 |
| Aspartate aminotransferase increasedInvestigations | 4/25 | 5/25 |
| RashSkin and subcutaneous tissue disorders | 0/25 | 2/25 |
| Back PainMusculoskeletal and connective tissue disorders | 2/25 | 0/25 |
| Age, Continuous(years) | Open-label Palivizumab (Part 1) | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) | Total |
|---|---|---|---|---|
| Mean | 25.67 ± 2.58 | 28.16 ± 6.30 | 26.76 ± 5.83 | 26.86 ± 4.90 |
| Sex: Female, Male(Participants) | Open-label Palivizumab (Part 1) | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) | Total |
|---|---|---|---|---|
| Female | 2 | 12 | 5 | 19 |
| Male | 4 | 13 | 20 | 37 |
| Race (NIH/OMB)(Participants) | Open-label Palivizumab (Part 1) | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 2 | 2 |
| White | 4 | 23 | 20 | 47 |
| More than one race | 2 | 2 | 2 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2020 to primary completion in Oct 2020, 3 months.
Results were first posted in Oct 2021, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palivizumab